Maze Therapeutics, Inc. (MAZE) vs Omeros Corporation (OMER)

Maze Therapeutics, Inc. and Omeros Corporation are both Biotechnology companies. Maze Therapeutics, Inc. and Omeros Corporation are of similar size ($1.5B and $1.5B). Maze Therapeutics, Inc. has negative trailing earnings, so its P/E is not meaningful; Omeros Corporation trades at 11.6×. Omeros Corporation has the higher net margin (128.4% vs 0.00%) and the higher return on invested capital (0.00% vs −112.4%). Across the 12 metrics below, Omeros Corporation leads on 8 and Maze Therapeutics, Inc. on 4.

Valuation

Metric MAZE OMER Biotechnology median
P/E n/m 11.65 7.88
P/S n/m 14.78 11.47
P/B 3.39 n/m 2.52
Price to free cash flow n/m n/m 21.16
EV/EBITDA n/m n/m 0.74
EV/Sales n/m 14.59 10.73
Earnings yield (9.67%) 8.58% (28.84%)
Free cash flow yield (6.95%) (4.78%) (23.03%)

Profitability

Metric MAZE OMER Biotechnology median
Gross margin — 37.57% 65.16%
Operating margin 0.00% (74.88%) 0.00%
Net margin 0.00% 128.36% 0.00%
Free cash flow margin 0.00% (70.69%) 0.00%
Return on equity (37.35%) (89.15%) (57.72%)
Return on assets (31.99%) 51.22% (49.22%)
Return on invested capital (112.36%) 0.00% 0.00%

Growth

Metric MAZE OMER Biotechnology median
Revenue growth (TTM) — 36.32% 5.64%
EPS growth (last fiscal year) (344.00%) 98.15% —
Revenue growth, 5-year CAGR — 40.44% 8.40%
Net income growth, 5-year CAGR — 0.00% 0.00%

Health

Metric MAZE OMER Biotechnology median
Debt to equity 0.09 (1.89) 0.00
Current ratio 18.31 1.95 4.73
Net debt to EBITDA 2.43 (0.30) 0.96

Dividend

Metric MAZE OMER Biotechnology median
Dividend yield — — 2.10%
Payout ratio — 0.00 0.00

Size

Metric MAZE OMER Biotechnology median
Market cap 1.48b 1.46b 162.10m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack